A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis

Carcinogenesis

Volumn 35, Issue 10, 2014, Pages 2291-2299

  Ho, Victor W ^a   J Hamilton, Melisa ^a   Dang, Ngoc Ha Thi ^b   E Hsu, Brian ^a   H Adomat, Hans ^c   S Guns, Emma ^c   Weljie, Aalim ^b   Samudio, Ismael ^a   L Bennewith, Kevin ^b   Krystal, Gerald ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; PROTEIN INTAKE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

AMINO ACID METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; LOW CARBOHYDRATE DIET; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DIET; RISK REDUCTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DIET THERAPY; DISEASE MODEL; LUNG NEOPLASMS; METABOLISM; NEOPLASM METASTASIS; PATHOLOGY; PHARMACOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; PROTEIN INTAKE; SECONDARY; TRANSGENIC MOUSE;

ANIMALS; DIET THERAPY; DIET, CARBOHYDRATE-RESTRICTED; DIETARY PROTEINS; DISEASE MODELS, ANIMAL; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 84925445932     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu147     Document Type: Article

References (35)

1. Khalid, S. et al. (2010) Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Res. Treat., 122, 647-659.
2. VanSaun, M.N. et al. (2009) High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am. J. Pathol., 175, 355-364.
3. Faber, J. et al. (2008) Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia. Br. J. Cancer, 99, 2029-2036.
4. Srivastava, M.K. et al. (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res., 70, 68-77.
5. Gunnerud, U.J. et al. (2012) Effects of pre-meal drinks with protein and amino acids on glycemic and metabolic responses at a subsequent composite meal. PLoS One, 7, e44731.
6. Ho, V.W. et al. (2011) A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res., 71, 4484-4493.
7. Bielohuby, M. et al. (2011) Induction of ketosis in rats fed low-carbohydrate, high-fat diets depends on the relative abundance of dietary fat and protein. Am. J. Physiol. Endocrinol. Metab., 300, E65-E76.
8. Magee, B.A. et al. (1979) The inhibition of malignant cell growth by ketone bodies. Aust. J. Exp. Biol. Med. Sci., 57, 529-539.
9. Basu, G.D. et al. (2006) Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol., 177, 2391-2402.
10. Brown, M.D. et al. (2006) Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. Br. J. Cancer, 94, 842-853.
11. DuBois, R.N. (2006) Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit? J. Clin. Oncol., 24, 2691-2693.
12. Wang, D. et al. (2004) Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc. Natl. Acad. Sci. USA, 101, 415-416.
13. Gatenby, R.A. et al. (2006) Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res., 66, 5216-5223.
14. Pulaski, B.A. et al. (2001) Mouse 4T1 breast tumor model. Curr. Protoc. Immunol., 20, 20.2.
15. Gingrich, J.R. et al. (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res., 56, 4096-4102.
16. Farshidfar, F. et al. (2012) Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med., 4, 42.
17. Matsuda, M. et al. (1996) Effect of estrogen on hyperprolactinemiainduced glucose intolerance in SHN mice. Proc. Soc. Exp. Biol. Med., 212, 243-247.
18. Guarente, L. (2008) Mitochondria-a nexus for aging, calorie restriction, and sirtuins? Cell, 132, 171-176.
19. Hursting, S.D. et al. (2010) Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis, 31, 83-89.
20. Menter, D.G. et al. (2010) Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin. Cancer Res., 16, 1384-1390.
21. Gameiro, P.A. et al. (2013) In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab., 17, 372-385.
22. Locasale, J.W. et al. (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet., 43, 869-874.
23. Santos, C.R. et al. (2012) Lipid metabolism in cancer. FEBS J., 279, 2610-2623.
24. Warburg, O. et al. (1927) The metabolism of tumors in the body. J. Gen. Physiol., 8, 519-530.
25. Kroemer, G. et al. (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell, 13, 472-482.
26. Thomlinson, R.H. et al. (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer, 9, 539-549.
27. Li, W. et al. (2013) Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts. Oncol. Lett., 5, 923-928.
28. Perroud, H.A. et al. (2013) Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol., 9, 451-462.
29. Zhang, B. et al. (2013) Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer. J. Cancer Res. Clin. Oncol., 139, 797-807.
30. Wang, D. et al. (2010) Eicosanoids and cancer. Nat. Rev. Cancer, 10, 181-193.
31. Zhou, J. et al. (2005) Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Res., 65, 657-663.
32. Long, X.H. et al. (2013) Tumor suppressive microRNA-424 inhibits osteosarcoma cell migration and invasion via targeting fatty acid synthase. Exp. Ther. Med., 5, 1048-1052.
33. Migita, T. et al. (2009) Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J. Natl. Cancer Inst., 101, 519-532.
34. Porta, R. et al. (2014) Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients. Menopause, 21, 188-191.
35. Puig, T. et al. (2009) Novel inhibitors of fatty acid synthase with anticancer activity. Clin. Cancer Res., 15, 7608-7615.